A metabolic profile of intensive care unit patients based on biomarkers of four metabolites can be used to accurately predict mortality, according to a new study.
[More]
Inflammation can be thought of as taking two major forms: acute or chronic. Acute inflammation, which can be painful, usually arises quickly and resolves quickly. It accompanies bacterial infections, traumatic injury and is useful to fight infections and promote healing.
[More]
Findings from two trials suggest that high-frequency oscillatory ventilation does not help, and may even harm patients with acute respiratory distress syndrome.
[More]
Amgen announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer.
[More]
Postoperative acute respiratory distress syndrome is rare in patients undergoing low-risk surgery, but still carries a very high mortality rate, a large study shows.
[More]
The World Health Organization has sent a team to Jordan at the request of the country’s Ministry of Health to help investigate the emergence of a novel coronavirus that resulted in the deaths of two people earlier this year, and to assist with further epidemiologic surveillance.
[More]
Serum procalcitonin is a useful marker for distinguishing between acute exacerbation of interstitial pneumonia and bacterial pneumonia, say researchers.
[More]
Among patients without acute respiratory distress syndrome, protective mechanical ventilation with use of lower tidal volumes (the volume of air inhaled and exhaled during each breath) was associated with better outcomes including less lung injury, lower mortality, fewer pulmonary infections and a shorter hospital length of stay, according to a meta-analysis of previous studies, reported in the October 24/31 issue of JAMA.
[More]
A major breakthrough in the development of a highly effective vaccine against the deadly Nipah virus has been reported by a team of federal and university scientists. The results of their study, "A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge," will appear in Science Translational Medicine online.
[More]
When hospital patients need assistance breathing and are placed on a mechanical ventilator for days at a time, their lungs react to the pressure generated by the ventilator with an out-of-control immune response that can lead to excessive inflammation, new research suggests.
[More]
Scientists have provided the first evidence that an enzyme called Eya1 protein phosphatase is a critical regulator of lung function and that this may have broad implications for sufferers of a variety of pulmonary diseases.
[More]
An international task force this week unveiled a revised definition of acute respiratory distress syndrome (ARDS), a disease first recognized during the Vietnam War in casualties with limb injuries who had trouble breathing.
[More]
Gordon D. Rubenfeld, M.D., of the Sunnybrook Health Sciences Center, Toronto, Canada, and colleagues with the ARDS (acute respiratory distress syndrome) Definition Task Force, developed a new definition of ARDS (the Berlin Definition) that focused on feasibility, reliability, validity and objective evaluation of its performance.
[More]
Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, reported that data from a preclinical study of SURFAXIN LS (lyophilized KL4 surfactant) was recently published in the May issue of Pediatric Research.
[More]
Queen's University and NUI Galway and are leading a clinical trial to investigate the possibility that statins, a drug commonly used to combat cholesterol, might help patients with acute severe respiratory failure.
[More]
Discovery Laboratories, Inc. today announced the presentation of a new pharmacoeconomic analysis demonstrating that the lower rate of reintubation previously reported in infants treated with SURFAXIN, when compared with infants treated with Curosurf® and Survanta®, the current global market leading surfactants, also resulted in a potential hospital cost savings of $160,000 to $252,000 per 100 infants.
[More]
Cognitive and psychiatric impairments are common among long-term survivors of acute lung injury (ALI), and these impairments can be assessed using a telephone-based test battery, according to a new study.
[More]
Carefully adjusting mechanical ventilator settings in the intensive care unit to pump smaller breaths into very sick lungs can reduce the chances of dying by as much as 8 percent, according to a study by critical care experts at Johns Hopkins. Study participants were evaluated for two years after their acute lung injury.
[More]
Over the last few decades there has been an explosion in the discovery of biomarkers for diagnosis, disease monitoring, and prognostic evaluation. In the April issue of Translational Research, entitled "Biomarkers: New Tools of Modern Medicine," an international group of medical experts explores the promise and challenges of biomarker discovery and highlights the latest advances in the use of biomarkers in various diseases.
[More]
Discovery Laboratories, Inc., a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced that the United States Food and Drug Administration (FDA) has approved SURFAXIN (lucinactant) for the prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDS.
[More]